Saving Lives Is More Important Than Abstract Moral Concerns: Financial Incentives Should Be Used to Increase Organ Donation

Annals of Thoracic Surgery

Volumn 88, Issue 4, 2009, Pages 1053-1061

  Hippen, Benjamin ^a   Ross, Lainie Friedman ^a   Sade, Robert M ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOETHICS; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; KIDNEY TRANSPLANTATION; MORALITY; ORGAN DONOR; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT;

FEES AND CHARGES; HUMANS; MORAL OBLIGATIONS; SOCIOECONOMIC FACTORS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS;

EID: 70249110431     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2009.06.087     Document Type: Article

References (57)

1. Removal reasons by year; Removed from the Waiting List: January, 1995-March 31, 2009. OPTN: Organ Procurement and Transplantation Network. http://optn.transplant.hrsa.gov/latestData/rptData.asp Accessed June 16, 2009
2. Gilbertson D.T., Liu J., and Xue J.L. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 16 (2005) 3736-3741
3. Hippen B. Preventive measures may not reduce the demand for kidney transplantation. There is reason to suppose this is not the case. Kidney Int 70 (2006) 606-607
4. Healy K. Do presumed consent laws raise organ procurement rates?. De Paul Law Rev 55 (2006) 1017-1043
5. Ibrahim H.N., Foley R., and Tan L. Long-term consequences of kidney donation. NEJM 360 (2009) 459-469
6. Hippen B.E. In defense of a regulated market in kidneys from living vendors. J Med Philos 30 (2005) 593-626
7. Hippen B. Organ sales and moral travails: lessons from the living kidney vendor program in Iran. Cato Policy Analysis, No 614. 2008. http://www.cato.org/pub_display.php?pub_id=9273 Accessed July 31, 2009
8. Hippen B.E. The case for kidney markets. The New Atlantis 14 (2006) 47-61. http://www.thenewatlantis.com/archive/14/hippen.htm Accessed July 31, 2009
9. S110, 2nd session. Organ Donation Clarification and Antitrafficking Act of 2008. http://fairfoundation.org/organdonation/specter_bill.pdf Accessed August 1, 2009
10. In: Childress J.F., and Liverman C.T. (Eds). Organ donation: opportunities for action. Report of the Institute of Medicine Committee on Increasing Rates of Organ Donation (2006), The National Academic Press, Washington, DC
11. The Organ Procurement and Transplantation Network, data reports. http://www.unos.org/data/about/viewDataReports.asp Accessed August 1, 2009
12. 2007 OPTN/SRTR annual report: transplant data 1997-2006, chapter IV: kidney and pancreas transplantation in the United States, 1997-2006: The HRSA breakthrough collaboratives and the 58 DSA challenge. http://www.ustransplant.org/annual_Reports/current/chapter_IV_forprint.pdf Accessed August 1, 2009
13. National Kidney Foundation. Organ shortage needs multi-faceted approach (January 29, 2009). http://www.medicalnewstoday.com/articles/137316.php Accessed August 1, 2009
14. National Organ Transplant Act Public Law 98-507 (October 19, 1984)
15. World Health Organization (WHO). WHO Guiding principles on human organ transplantation. Lancet 337 (1991) 1470-1471
16. World Health Organization (WHO). WHO Guiding principles on human organ transplantation (May 26, 2008). http://www.searo.who.int/LinkFiles/BCT_WHO_guidingprinciples_organ_transplantation.pdf Accessed August 1, 2009
17. Cherry M.J. Kidney for sale by owner: human organs, transplantation and the market (2005), Georgetown University Press, Washington, DC
18. Taylor J.S. Stakes and kidneys: why markets in human body parts are morally imperative (2005), Ashgate Publishing Lmtd, Hampshire, England
19. Goodwin M. Black markets: the supply and demand of body parts (2006), Cambridge University Press, New York, NY
20. Richards J.R. Nephrarious goings on. Kidney sales and moral arguments. J Med Philos 21 (1996) 357-373
21. Matas A.J. The case for living kidney sales: rationale, objections and concerns. Am J Transplant 4 (2004) 2007-2017
22. Gill M.B., and Sade R.M. Paying for kidneys: the case against prohibition. Kennedy Inst Ethics J 12 (2002) 17-45
23. Hippen B.E. In defense of a regulated market in kidneys from living vendors. J Med Philos 30 (2005) 593-626
24. Beauchamp T.L., and Childress J.F. Principles of biomedical ethics. 5th ed. (2001), Oxford University Press, New York, NY
25. Jonsen A., Siegler M., and Winslade W. Clinical ethics. a practical approach to ethical decisions in clinical medicine. 6th ed. (2006), McGraw-Hill Companies Inc, New York
26. Veatch R.M. Transplantation Ethics (2000), Georgetown University Press, Washington DC
27. Friedman E.A., and Friedman A.L. Payment for donor kidneys: pros and cons. Kidney Int 69 (2006) 960-962
28. Friedlaender M.M. The role of commercial non-related living kidney transplants. J Nephrology 16 suppl 7 (2003) S10-S15
29. Satel S. Organs for sale. The American (October 14, 2006). http://american.com/archive/2006/november/organs-for-sale Accessed February 2, 2009
30. Adams A.F., Barnett A.H., and Kaserman D.L. Markets of organs: the question of supply. Contemp Econ Policy 17 (1999) 147-155
31. Ghods A.J., and Savaj S. Iranian model of paid and regulated living-unrelated kidney donation. Clin J Am Soc Nephrol 1 (2006) 1136-1145
32. Radcliffe-Richards J., Daar A.S., Guttmann R.D., et al. The case for allowing kidney sales. International forum for transplant ethics. Lancet 351 9120 (1988) 1950-1952
33. Levine D.Z. Kidney vending: "Yes!" or "No!". Am J Kidney Dis 35 (2000) 1002-1018
34. Holmes Jr. O.W. Quote available at. http://thinkexist.com/quotation/the_right_to_swing_my_fist_ends_where_the_other/217369.html Accessed August 1, 2009
35. Sandel M.J. What money can't buy: the moral limits of markets. The Tanner lectures on human values delivered at Brasenose College, Oxford, May 11-12, 1998. http://www.tannerlectures.utah.edu/lectures/documents/sandel00.pdf Accessed August 1, 2009
36. Lawler P.A. Is the body property?. The New Atlantis. Fall (2006) 62-72
37. Kass L. Life, liberty, and the defense of dignity: the challenge for bioethics (2004), Encounter Books, San Francisco CA
38. Crouch R.A., and Elliott C. Moral agency and the family: the case of living related organ transplantation. Camb Q Healthc Ethics 8 (1999) 275-287
39. Barnett W., Saliba M., and Walker D. A free market in kidneys: efficient and equitable. Indep Rev V (2001) 373-383
40. Becker G.S., and Elias J.J. Introducing incentives in the market for live and cadaveric organ donations. J Econ Perspect 21 (2007) 3-24. http://www.atyponlink.com/AEAP/doi/pdf/10.1257/jep.21.3.3?cookieSet=1 Accesssed August 1, 2009
41. Matas A.J., and Schnitzler M. "Payment for living donor (vendor) kidneys: a cost-effectiveness analysis,". Am J Transplant 4 (2004) 216-221
42. Monaco A.P. Rewards for organ donation: the time has come. Kidney Int 69 (2006) 955-957
43. Erin C.A., and Harris J. An ethical market in human organs. J Med Ethics 29 (2003) 137-138
44. Brennan T. Markets in health care: the case of renal transplantation. J Law, Med Ethics 35 (2007) 249-255
45. Jha V., and Chugh K.S. The case against a regulated system of living kidney sales. Nat Clin Pract Nephrol 2 (2006) 466-467
46. Rizvi S.N.S., Zafar M., Ahmed E., et al. Health status and renal function evaluation of kidney venders: a report from Pakistan. Am J Transplant 13 (2008) 453-476
47. Radin M.J. Contested commodities: the trouble with trade in sex, children, body parts an oher things (1996), Harvard University Press, Cambridge, MA
48. Rivera-Lopez E. Organ sales and moral distress. J Appl Philos 23 (2006) 41-52
49. Danovitch G.M. The doctor-patient relationship in living donor kidney transplantation. Curr Opin Nephrol Hypertens 16 (2007) 503-505
50. Frade I.C., Fonseca I., Dias L., et al. Impact assessment in living kidney donation: psychosocial aspects in the donor. Transplant Proc 40 (2008) 677-681
51. Johnson E.M., Anderson J.K., Jacobs C., et al. Long-term follow-up of living kidney donors: quality of life after donation. Transplantation 67 (1999) 717-721
52. Goyal M., Mehta R.L., Schneiderman L.J., and Sehgal A.R. Economic and health consequences of selling a kidney in India. JAMA 288 (2002) 1589-1593
53. Zargooshi J. Quality of life of Iranian kidney "donors.". J Urol 166 (2001) 1790-1799
54. Rawls J. A theory of justice (1971), Belknap Press of Harvard University Press, Cambridge, MA
55. Assessing initiatives to increase organ donations: hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives (June 3, 2003). http://archives.energycommerce.house.gov/reparchives/108/Hearings/06032003hearing946/print.htm Accessed June 16, 2009
56. Robeznieks A. Bill would allow studies on organ donation incentives. AMNews (August 11, 2003). http://www.ama-assn.org/amednews/2003/08/11/prsb0811.htm#w1 Accessed June 16, 2009
57. Pitney J.J. Incentives for organ donation. Politcalmavens.com (December 2, 2008). http://politicalmavens.com/index.php/2008/12/02/incentives-for-organ-donation/ Accessed June 16, 2009